Exosomal Tau Biomarker Detection via Lateral Flow Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE) are inadequate for early stage detection, relying on invasive and costly procedures like MRI and lumbar punctures, which are inconvenient and often unreliable, lacking sensitivity and specificity for early-stage diagnosis and monitoring.
Innovation Solution
Development of point-of-care diagnostics using lateral flow devices (LFDs) that detect biomarkers in biological samples by isolating and characterizing brain-specific extracellular vesicles, such as exosomes, containing antigens like tau, β-amyloid, and other neural markers, providing a non-invasive and cost-effective means for early detection and monitoring of brain injuries.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive procedures like lumbar puncture and MRI are used for diagnosis, then diagnostic accuracy is improved, but patient convenience and cost-effectiveness deteriorate
Solution Approach 1:
The patent uses exosomes as intermediary carriers to transport brain biomarkers from the central nervous system to peripheral blood. This mediator enables non-invasive detection of brain pathology through blood tests, eliminating the need for invasive lumbar punctures while maintaining diagnostic accuracy through the exosomal biomarker signature.
Solution Approach 2:
The patent replaces mechanical/invasive diagnostic procedures (lumbar puncture, MRI) with a biochemical detection system. By detecting exosomal biomarkers in blood using molecular assays, the system substitutes invasive mechanical procedures with non-invasive biochemical analysis, improving patient convenience while maintaining diagnostic precision.
2Measurement precision
If traditional diagnostic methods are used, then diagnostic accuracy is improved, but cost and time consumption increase
Solution Approach 1:
The patent extracts and isolates exosomes from blood samples, concentrating the relevant biomarkers into a separate fraction. This extraction process enables rapid detection of brain pathology markers without requiring time-consuming invasive procedures or complex imaging sequences, reducing overall diagnostic time while maintaining accuracy.
Solution Approach 2:
The patent changes the detection parameter from direct measurement of brain tissue or CSF (requiring invasive procedures) to measurement of exosomal biomarkers in blood. This parameter transformation enables faster, non-invasive diagnostics while maintaining diagnostic accuracy through the specific biomarker signature carried by exosomes.
3Measurement precision
If invasive procedures are used for biomarker detection, then measurement accuracy is improved, but device complexity and invasiveness increase
Solution Approach 1:
The patent employs exosomes as a natural intermediary that simplifies the detection process. Instead of directly accessing complex brain tissue or CSF, the system detects simplified exosomal biomarker signatures in blood, reducing procedural complexity while maintaining measurement accuracy through the exosomal carrier system.
Solution Approach 2:
The patent creates a molecular copy of brain pathology information through exosomes. The exosomes carry replicated biomarker signatures that reflect brain state, enabling accurate detection without directly sampling the complex brain environment, thus simplifying the diagnostic procedure while preserving measurement precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables reliable, rapid, and inexpensive detection of brain injuries and diseases like CTE and Alzheimer's, offering early intervention opportunities and improving diagnostic accuracy through stable and sensitive measurement of exosomal biomarkers.
Implementation Method 1
extracellular vesicles, such as exosomes, which contain biomarkers including peptides, proteins, and/or nucleic acids that indicate the presence of a brain injury
Implementation Method 2
methods, compositions, devices, and kits for isolating, identifying, measuring, detecting, and analyzing extracellular vesicles, such as exosomes, which contain biomarkers
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are methods, compositions, devices, and kits for the isolation of brain- specific exosomes. Specifically, methods, compositions, devices, and kits comprising an isolated brain-specific extracellular vesicle or exosome joined to a first binding agent that is specific for tau, β-amyloid, S100 β, neuron-specific enolase, glycoprotein A2B5, CD133, NQ01, synaptophysin, neuronal nuclei, MAB1569, polysialic acid-neural cell adhesion molecule (PSA-NCAM), or neurogenic differentiation 1 (NeuroD or Beta2), or glycosylated or phosphorylated forms of these molecules, are provided.